Business Desk :
Merck Sharp & Dohme (MSD), a global healthcare company of USA, has announced a strategic partnership with Healthcare Pharmaceuticals Limited (HPL), Bangladesh at a city hotel on Wednesday.
The new partnership will enable MSD to bring its best-in-class and first-in-class products for patients in Bangladesh. Through this partnership, MSD plans to launch 5 new products in vaccines and various therapeutic categories. With HPL’s strong footprint across Bangladesh comprising a 1500-people sales force and a wide distribution channel with 23 depots, this partnership will expand the reach for MSD’s innovative product portfolio to a much larger base of healthcare providers and patients. The alliance aims to collaborate with key stakeholders and healthcare providers in Bangladesh for disease education and capacity building initiatives.
Speaking on the occasion, KG Ananthakrishnan, President and Managing Director of MSD in South Asia Region said, “We are delighted to announce this strategic partnership with Healthcare Pharmaceuticals as it will help to create access to MSD’s best-in-class, innovative products and collaborate for scientific expertise with leading medical institutions and healthcare providers in the country for working towards enhanced patient management and care in Bangladesh. MSD is committed to Bangladesh both in terms of bringing global quality products and helping to reduce the disease burden in the country through our unique beyond-the-pill approach.”
Talking about the partnership, Muhammad Halimuzzaman, Chief Executive Officer of HPL said, “We are proud to join hands with MSD to bring their portfolio of products to Bangladesh. I am certain that our strong footprint in the country, combined with MSD’s innovative product portfolio, will help us contribute to the health and lives of people in the country.”
Merck Sharp & Dohme (MSD), a global healthcare company of USA, has announced a strategic partnership with Healthcare Pharmaceuticals Limited (HPL), Bangladesh at a city hotel on Wednesday.
The new partnership will enable MSD to bring its best-in-class and first-in-class products for patients in Bangladesh. Through this partnership, MSD plans to launch 5 new products in vaccines and various therapeutic categories. With HPL’s strong footprint across Bangladesh comprising a 1500-people sales force and a wide distribution channel with 23 depots, this partnership will expand the reach for MSD’s innovative product portfolio to a much larger base of healthcare providers and patients. The alliance aims to collaborate with key stakeholders and healthcare providers in Bangladesh for disease education and capacity building initiatives.
Speaking on the occasion, KG Ananthakrishnan, President and Managing Director of MSD in South Asia Region said, “We are delighted to announce this strategic partnership with Healthcare Pharmaceuticals as it will help to create access to MSD’s best-in-class, innovative products and collaborate for scientific expertise with leading medical institutions and healthcare providers in the country for working towards enhanced patient management and care in Bangladesh. MSD is committed to Bangladesh both in terms of bringing global quality products and helping to reduce the disease burden in the country through our unique beyond-the-pill approach.”
Talking about the partnership, Muhammad Halimuzzaman, Chief Executive Officer of HPL said, “We are proud to join hands with MSD to bring their portfolio of products to Bangladesh. I am certain that our strong footprint in the country, combined with MSD’s innovative product portfolio, will help us contribute to the health and lives of people in the country.”
